Skip to content
2000
Volume 20, Issue 2
  • ISSN: 1574-888X
  • E-ISSN: 2212-3946

Abstract

Background

Human Platelet Lysate (hPL) is a platelet-derived and growth factor-rich supplement for cell culture. It can be prepared from surplus platelet concentrates initially intended for transfusion. Amotosalen-based photochemical pathogen inactivation of platelet concentrates is used in a number of blood establishments worldwide to minimize the risk of pathogen transmission from donor to patient.

Methods

This pathogen inactivation method has not been formally validated for direct use on hPL. Here, we have studied the impact of pathogen inactivation on hPL and compared it to untreated hPL prepared from pathogen-inactivated platelet concentrates or control hPL. We used mass spectrometry, ELISA, and mesenchymal stem cell culture for determining residual amotosalen, final growth factor content, and cell doubling, respectively.

Results

The data have shown amotosalen concentrations to be reduced a thousand-fold following pathogen inactivation, leaving trace quantities of photosensitizer molecules in the final hPL product. Some growth factors have been reported to be significantly more impacted in hPL that is directly pathogen-inactivated compared to both control conditions. This has no significant effect on the growth kinetics of adipose-derived mesenchymal stem cells.

Conclusion

Direct amotosalen-based pathogen inactivation has a measurable impact on certain growth factors in hPL, but this does not outweigh the likely benefits of reducing the odds of donor-to-patient pathogen transmission.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cscr/10.2174/011574888X307274240610113314
2024-06-20
2025-09-01

  • From This Site

    /content/journals/cscr/10.2174/011574888X307274240610113314
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. DoucetC. ErnouI. ZhangY. LlenseJ.R. BegotL. HolyX. LatailladeJ.J. Platelet lysates promote mesenchymal stem cell expansion: A safety substitute for animal serum in cell-based therapy applications.J. Cell. Physiol.2005205222823610.1002/jcp.2039115887229
     [Google Scholar]
  2. SchallmoserK. BartmannC. RohdeE. ReinischA. KashoferK. StadelmeyerE. DrexlerC. LanzerG. LinkeschW. StrunkD. Human platelet lysate can replace fetal bovine serum for clinical-scale expansion of functional mesenchymal stromal cells.Transfusion20074781436144610.1111/j.1537‑2995.2007.01220.x17655588
     [Google Scholar]
  3. BurnoufT. StrunkD. KohM.B.C. SchallmoserK. Human platelet lysate: Replacing fetal bovine serum as a gold standard for human cell propagation?Biomaterials20167637138710.1016/j.biomaterials.2015.10.06526561934
     [Google Scholar]
  4. HenschlerR. GabrielC. SchallmoserK. BurnoufT. KohM.B.C. Human platelet lysate current standards and future developments.Transfusion20195941407141310.1111/trf.1517430741431
     [Google Scholar]
  5. OellerM. Laner-PlambergerS. KrischL. RohdeE. StrunkD. SchallmoserK. Human platelet lysate for good manufacturing practice-compliant cell production.Int. J. Mol. Sci.20212210517810.3390/ijms2210517834068404
     [Google Scholar]
  6. BlümelJ. SchwantesA. BaylisS.A. StühlerA. Strategies toward virus and prion safe human platelet lysates.Transfusion202060121922010.1111/trf.1558131898348
     [Google Scholar]
  7. BrodersenT. RostgaardK. LauC.J. JuelK. ErikstrupC. NielsenK.R. OstrowskiS.R. TitlestadK. SækmoseS.G. PedersenO.B.V. HjalgrimH. The healthy donor effect and survey participation, becoming a donor and donor career.Transfusion202363114315510.1111/trf.1719036479702
     [Google Scholar]
  8. FeysH.B. Van AelstB. CompernolleV. Biomolecular consequences of platelet pathogen inactivation methods.Transfus. Med. Rev.2019331293410.1016/j.tmrv.2018.06.00230021699
     [Google Scholar]
  9. DelabieW. De BleserD. VandewalleV. VandekerckhoveP. CompernolleV. FeysH.B. Single step method for high yield human platelet lysate production.Transfusion202363237338310.1111/trf.1718836426732
     [Google Scholar]
  10. HardwickJ. Blood processing.ISBT Sci. Ser.20083214817610.1111/j.1751‑2824.2008.00195.x
     [Google Scholar]
  11. Van AelstB. FeysH.B. DevlooR. VanhoorelbekeK. VandekerckhoveP. CompernolleV. Riboflavin and amotosalen photochemical treatments of platelet concentrates reduce thrombus formation kinetics in vitro.Vox Sang.2015108432833910.1111/vox.1223125557250
     [Google Scholar]
  12. Van AelstB. DevlooR. ZachéeP. t’KindtR. SandraK. VandekerckhoveP. CompernolleV. FeysH.B. Psoralen and ultraviolet a light treatment directly affects phosphatidylinositol 3-kinase signal transduction by altering plasma membrane packing.J. Biol. Chem.201629147243642437610.1074/jbc.M116.73512627687726
     [Google Scholar]
  13. MatthyssenS. Ní DhubhghaillS. Van GerwenV. ZakariaN. Xeno-free cultivation of mesenchymal stem cells from the corneal stroma.Invest. Ophthalmol. Vis. Sci.20175852659266510.1167/iovs.17‑2167628524929
     [Google Scholar]
  14. JanetzkoK. LinL. EichlerH. MayaudonV. FlamentJ. KlüterH. Implementation of the intercept blood system for platelets into routine blood bank manufacturing procedures: Evaluation of apheresis platelets.Vox Sang.200486423924510.1111/j.0042‑9007.2004.00419.x15144528
     [Google Scholar]
  15. Fernandez-RebolloE. MentrupB. EbertR. FranzenJ. AbagnaleG. SiebenT. OstrowskaA. HoffmannP. RouxP.F. RathB. GoodhardtM. LemaitreJ.M. BischofO. JakobF. WagnerW. Human platelet lysate versus fetal calf serum: These supplements do not select for different mesenchymal stromal cells.Sci. Rep.201771513210.1038/s41598‑017‑05207‑128698620
     [Google Scholar]
  16. HaraY. SteinerM. BaldiniM.G. Platelets as a source of growth-promoting factor(s) for tumor cells.Cancer Res.1980404121212167357550
     [Google Scholar]
  17. BiebackK.A.R.E.N. Fernandez-MuñozB. PatiS. SchäferR. Gaps in the knowledge of human platelet lysate as a cell culture supplement for cell therapy: A joint publication from the AABB and the International Society for Cell & Gene Therapy.Cytotherapy201921991192410.1016/j.jcyt.2019.06.00631307904
     [Google Scholar]
  18. StühlerA. BlümelJ. Spezifische aspekte zur virussicherheit von produktionshilfsstoffen für somatische zelltherapie-arzneimittel.Federal Health Gazette Health Res. Health Protect20155811-121233123810.1007/s00103‑015‑2238‑y26383536
     [Google Scholar]
  19. ViauS. EapS. ChabrandL. LagrangeA. DelormeB. Viral inactivation of human platelet lysate by gamma irradiation preserves its optimal efficiency in the expansion of human bone marrow mesenchymal stromal cells.Transfusion20195931069107910.1111/trf.1520530793328
     [Google Scholar]
  20. LeeY.L. LeeL.W. SuC.Y. HsiaoG. YangY.Y. LeuS.J. ShiehY.H. BurnoufT. Virally inactivated human platelet concentrate lysate induces regulatory T cells and immunosuppressive effect in a murine asthma model.Transfusion20135391918192810.1111/trf.1206823305248
     [Google Scholar]
  21. WollowitzS. Targeting DNA and RNA in pathogens: Mode of action of amotosalen HCl.Transfus. Med. Hemother.2004311111610.1159/000076975
     [Google Scholar]
  22. CFRCode of Federal Regulations, general biological products standards, constituent materials.2002Available From: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=610&showFR=1
  23. CastigliaS. MareschiK. LabancaL. LucaniaG. LeoneM. SanavioF. CastelloL. RustichelliD. SignorinoE. GunettiM. BergalloM. BordigaA.M. FerreroI. FagioliF. Inactivated human platelet lysate with psoralen: A new perspective for mesenchymal stromal cell production in Good Manufacturing Practice conditions.Cytotherapy201416675076310.1016/j.jcyt.2013.12.00824529555
     [Google Scholar]
  24. Jonsdottir-BuchS.M. SigurgrimsdottirH. LiederR. SigurjonssonO.E. Expired and pathogen-inactivated platelet concentrates support differentiation and immunomodulation of mesenchymal stromal cells in culture.Cell Transplant.20152481545155410.3727/096368914X68304325198449
     [Google Scholar]
  25. IudiconeP. FioravantiD. BonannoG. MiceliM. LavorinoC. TottaP. FratiL. NutiM. PierelliL. Pathogen-free, plasma-poor platelet lysate and expansion of human mesenchymal stem cells.J. Transl. Med.20141212810.1186/1479‑5876‑12‑2824467837
     [Google Scholar]
  26. NebieO. DevosD. VingtdeuxV. BarroL. DevedjianJ.C. JonneauxA. ChouM.L. BordetR. BuéeL. KnutsonF. BlumD. BurnoufT. The neuroprotective activity of heat-treated human platelet lysate biomaterials manufactured from outdated pathogen-reduced (amotosalen/UVA) platelet concentrates.J. Biomed. Sci.20192618910.1186/s12929‑019‑0579‑931666073
     [Google Scholar]
  27. ChristensenC. Jonsdottir-BuchS.M. SigurjonssonO.E. Effects of amotosalen treatment on human platelet lysate bioactivity: A proof-of-concept study.PLoS One2020154e022016310.1371/journal.pone.022016332294080
     [Google Scholar]
  28. ShanbhagS. Mohamed-AhmedS. LundeT.H.F. SulimanS. BolstadA.I. HervigT. MustafaK. Influence of platelet storage time on human platelet lysates and platelet lysate- expanded mesenchymal stromal cells for bone tissue engineering.Stem Cell Res. Ther.202011135110.1186/s13287‑020‑01863‑932962723
     [Google Scholar]
/content/journals/cscr/10.2174/011574888X307274240610113314
Loading
The Impact of Amotosalen Photochemical Pathogen Inactivation on Human Platelet Lysate
Curr Stem Cell Res Ther 20, 218 (2025); https://doi.org/10.2174/011574888X307274240610113314
/content/journals/cscr/10.2174/011574888X307274240610113314
/content/journals/cscr/10.2174/011574888X307274240610113314
Loading

Data & Media loading...


  • Article Type:     Research Article
Keyword(s): amotosalen; Human platelet lysate; mass spectrometry; mesenchymal stem cells; pathogen inactivation; stem cells

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test